SOAT1 and COVID-19: As JAK inhibitors attenuate JAK signaling and subsequent cytokine release, their administration may best be suited for patients with progressing COVID-19 who have not yet experienced a cytokine storm.[40] By contrast, as Type I interferons induce cellular antiviral states via the JAK/STAT pathway, its administration may be most efficacious early on in disease progression where the virus is still replicating.